<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038896</url>
  </required_header>
  <id_info>
    <org_study_id>0600B5-353</org_study_id>
    <nct_id>NCT00038896</nct_id>
  </id_info>
  <brief_title>Study Evaluating Venlafaxine ER in Adults With Panic Disorder</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy, safety, and tolerability of
      a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in
      the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">343</enrollment>
  <condition>Panic Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine ER</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female outpatient

          -  Be at least 18 years of age and legal age of consent

          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before
             study day 1

        Exclusion Criteria:

          -  Treatment with venlafaxine (IR or ER) within 6 months of study day 1

          -  Known hypersensitivity to venlafaxine (IR or ER) or related compounds

          -  History or presence of any clinically important hepatic, renal, or other medical
             disease that might compromise the study or be detrimental to the patient (eg,
             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
             cell epithelioma], uncontrolled hypertension)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2002</study_first_submitted>
  <study_first_submitted_qc>June 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2002</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <keyword>Panic</keyword>
  <keyword>Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

